Cargando…

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design

Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan-Ruide, Ochoa, Christopher J., Zhu, Yichen, Kramer, Adam, Wilson, Matthew, Fang, Ying, Chen, Yuning, Singh, Tanya, Di Bernardo, Gabriella, Zhu, Enbo, Lee, Derek, Moatamed, Neda A., Bando, Joanne, Zhou, Jin J., Memarzadeh, Sanaz, Yang, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558812/
https://www.ncbi.nlm.nih.gov/pubmed/37810241
http://dx.doi.org/10.1016/j.isci.2023.107952
_version_ 1785117363869319168
author Li, Yan-Ruide
Ochoa, Christopher J.
Zhu, Yichen
Kramer, Adam
Wilson, Matthew
Fang, Ying
Chen, Yuning
Singh, Tanya
Di Bernardo, Gabriella
Zhu, Enbo
Lee, Derek
Moatamed, Neda A.
Bando, Joanne
Zhou, Jin J.
Memarzadeh, Sanaz
Yang, Lili
author_facet Li, Yan-Ruide
Ochoa, Christopher J.
Zhu, Yichen
Kramer, Adam
Wilson, Matthew
Fang, Ying
Chen, Yuning
Singh, Tanya
Di Bernardo, Gabriella
Zhu, Enbo
Lee, Derek
Moatamed, Neda A.
Bando, Joanne
Zhou, Jin J.
Memarzadeh, Sanaz
Yang, Lili
author_sort Li, Yan-Ruide
collection PubMed
description Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the molecular and cellular characteristics of OC are urgently needed. Here, we conducted a comprehensive analysis of primary tumor cells and their microenvironment from 16 chemonaive and 10 recurrent OC patient samples. Profiling OC tumor biomarkers allowed for the identification of potential molecular targets for developing immunotherapies, while profiling the microenvironment yielded insights into its cellular composition and property changes between chemonaive and recurrent samples. Notably, we identified CD1d as a biomarker of the OC microenvironment and demonstrated its targeting by invariant natural killer T (iNKT) cells. Overall, our study presents a comprehensive immuno-profiling of OC tumor and microenvironment during disease progression, guiding the development of immunotherapies for OC treatment, especially for recurrent disease.
format Online
Article
Text
id pubmed-10558812
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105588122023-10-08 Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design Li, Yan-Ruide Ochoa, Christopher J. Zhu, Yichen Kramer, Adam Wilson, Matthew Fang, Ying Chen, Yuning Singh, Tanya Di Bernardo, Gabriella Zhu, Enbo Lee, Derek Moatamed, Neda A. Bando, Joanne Zhou, Jin J. Memarzadeh, Sanaz Yang, Lili iScience Article Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the molecular and cellular characteristics of OC are urgently needed. Here, we conducted a comprehensive analysis of primary tumor cells and their microenvironment from 16 chemonaive and 10 recurrent OC patient samples. Profiling OC tumor biomarkers allowed for the identification of potential molecular targets for developing immunotherapies, while profiling the microenvironment yielded insights into its cellular composition and property changes between chemonaive and recurrent samples. Notably, we identified CD1d as a biomarker of the OC microenvironment and demonstrated its targeting by invariant natural killer T (iNKT) cells. Overall, our study presents a comprehensive immuno-profiling of OC tumor and microenvironment during disease progression, guiding the development of immunotherapies for OC treatment, especially for recurrent disease. Elsevier 2023-09-19 /pmc/articles/PMC10558812/ /pubmed/37810241 http://dx.doi.org/10.1016/j.isci.2023.107952 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Li, Yan-Ruide
Ochoa, Christopher J.
Zhu, Yichen
Kramer, Adam
Wilson, Matthew
Fang, Ying
Chen, Yuning
Singh, Tanya
Di Bernardo, Gabriella
Zhu, Enbo
Lee, Derek
Moatamed, Neda A.
Bando, Joanne
Zhou, Jin J.
Memarzadeh, Sanaz
Yang, Lili
Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
title Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
title_full Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
title_fullStr Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
title_full_unstemmed Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
title_short Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
title_sort profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558812/
https://www.ncbi.nlm.nih.gov/pubmed/37810241
http://dx.doi.org/10.1016/j.isci.2023.107952
work_keys_str_mv AT liyanruide profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT ochoachristopherj profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT zhuyichen profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT krameradam profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT wilsonmatthew profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT fangying profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT chenyuning profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT singhtanya profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT dibernardogabriella profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT zhuenbo profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT leederek profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT moatamednedaa profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT bandojoanne profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT zhoujinj profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT memarzadehsanaz profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign
AT yanglili profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign